Long‐term outcome following imatinib therapy for chronic myelogenous leukemia, with assessment of dosage and blood levels: the JALSG CML202 study

A prospective multicenter Phase II study was performed to examine the efficacy and safety of imatinib therapy in newly diagnosed Japanese patients with chronic‐phase CML. Patients were scheduled to receive imatinib 400 mg daily. Plasma imatinib concentrations were measured by liquid chromatography–t...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Sci
Main Authors: Ohnishi, Kazunori, Nakaseko, Chiaki, Takeuchi, Jin, Fujisawa, Shin, Nagai, Tadashi, Yamazaki, Hirohito, Tauchi, Tetsuzo, Imai, Kiyotoshi, Mori, Naoki, Yagasaki, Fumiharu, Maeda, Yasuhiro, Usui, Noriko, Miyazaki, Yasushi, Miyamura, Koichi, Kiyoi, Hitoshi, Ohtake, Shigeki, Naoe, Tomoki
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2012
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7685081/
https://ncbi.nlm.nih.gov/pubmed/22364419
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1349-7006.2012.02253.x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados